RTP Mobile Logo
Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Urothelial Bladder Cancer (Webinar Video Proceedings)
Released March 2023

Featuring perspectives from Dr Matthew Galsky, Dr Jonathan Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Elisabeth Heath. Published March 15, 2023. (Webinar Video Proceedings)

CE Information and Faculty Disclosures

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of urothelial bladder cancer.


    • Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
    • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this strategy.
    • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for patients with metastatic urothelial bladder cancer (UBC).
    • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in clinical practice.
    • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these therapies would be appropriate.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
    • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for UBC.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:

    Matthew D Galsky, MD
    Professor of Medicine
    Icahn School of Medicine at Mount Sinai
    Co-Leader, Bladder Cancer Center of Excellence
    Associate Director, Translational Research
    The Tisch Cancer Institute
    New York, New York

    Advisory Committee: Aileron Therapeutics Inc, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, BioMotiv, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Dracen Pharmaceuticals, Dragonfly Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Incyte Corporation, Infinity Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Numab, Pfizer Inc, Seagen Inc, UroGen Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck.

    Jonathan E Rosenberg, MD
    Chief, Genitourinary Medical Oncology Service
    Division of Solid Tumor Oncology
    Enno W Ercklentz Chair
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Astellas, Seagen Inc, Tyra Biosciences; Consulting Agreements: Aadi Bioscience, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Imvax Inc, Infinity Pharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Lilly, Merck, Mirati Therapeutics Inc, Pfizer Inc, QED Therapeutics, Seagen Inc, Tyra Biosciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc; Honoraria: EMD Serono Inc, Pfizer Inc.

    Arlene Siefker-Radtke, MD
    Department of Genitourinary Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bristol-Myers Squibb Company, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IDEAYA Biosciences, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, Nektar, Seagen Inc, Taiho Oncology Inc; Contracted Research: Basilea Pharmaceutica Ltd, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Nektar, Takeda Pharmaceuticals USA Inc; Honoraria: Janssen Biotech Inc.


    Elisabeth I Heath, MD
    Associate Center Director, Translational Sciences
    Chair, Genitourinary Oncology Multidisciplinary Team
    Professor of Oncology and Medicine
    Hartmann Endowed Chair for Prostate Cancer Research
    Director, Prostate Cancer Research
    Karmanos Cancer Institute
    Wayne State University School of Medicine
    Detroit, Michigan

    Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi; Consulting Agreement: Astellas; Contracted Research: Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, BioXcel Therapeutics Inc, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffman-La Roche Ltd, Five Prime Therapeutics Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Merck, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Modra Pharmaceuticals, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Honoraria: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Genzyme Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Seagen Inc; Speakers Bureau: Sanofi; Nonrelevant Financial Relationship: Calibr.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: March 2023
    Expiration date: March 2024

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky

Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg

Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke

Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath

Select Publications